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598Blood Dendritic Cells Suppress NK Cell Function
and Increase the Risk of Leukemia Relapse after
Hematopoietic Cell Transplantation
Antonio Perez-Martinez,1,2 Rekha Iyengar,1 Kwan Gan,1 Thirachit Chotsampancharoen,1
Barbara Rooney,1 Marti Holladay,1 Manuel Ramırez,2 Wing Leung1,3NK cells play an important role in hematopoietic stem cell transplantation (HCT) and in cross talk with den-
dritic cells (DCs) to induce primary T cell response against infection. Therefore, we hypothesized that blood
DCs should augment NK cell function and reduce the risk of leukemia relapse after HCT. To test this hypoth-
esis, we conducted laboratory and clinical studies in parallel.We found that although, phenotypically, NK cells
could induce DC maturation and DCs could in turn increase activating marker expression on NK cells,
paradoxically, both BDCA11 myeloid DCs and BDCA41 plasmacytoid DCs suppressed the function of
NK cells. Patients who received an HLA-haploidentical graft containing a larger number of BDCA11 DCs
or BDCA41 DCs had a higher risk of leukemia relapse and poorer survival. Further experiments indicated
that the potent inhibition on NK cell cytokine production and cytotoxicity was mediated in part through the
secretion of IL-10 by BDCA11DCs and IL-6 by BDCA41DCs. These results have significant implications for
future HCT strategies.
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cellINTRODUCTION
Natural killer (NK) cells play an important role in
hematopoietic stem cell transplantation (HCT) for leu-
kemia [1-4]. It has been demonstrated that donor NK
cells may promote engraftment, prevent graft-versus
host disease (GVHD), control infections, and reduce
the risk of leukemia relapse. We and others have dem-
onstrated that NK cell alloreactivity is affected by
many determinants, including donor-versus-recipient
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leukin (IL)-12 and IL-18 [1,5-7]. Furthermore, the
potency of NK activity appears to be augmented
by a lymphopenic environment, especially T cell
lymphopenia because T cell alloreactivity dominates
that of NK cells [8].
Besides the interaction with T cells, we began to
investigate the interactions of human NK cells with
dendritic cells (DCs) and examined their effects on
patient outcomes after HCT. Blood DCs are not
a single cell type but consist of several distinct subsets,
including myeloid and lymphoid/plasmacytoid DC
(pDC) that are derived from common myeloid
and lymphoid progenitors, respectively [9,10]. The
interactions between DCs and NK cells have been
well documented [11-15]. For instance, in infection,
it is well known that DCs and NK cells crosstalk to
induce primary T cell response [14,16]. Both NK
cells and DCs are part of the innate immune
response system and are equipped with a large array
of pattern recognition receptors (PRRs) that allow
the recognition of different pathogens [17]. Toll-like
receptors (TLRs) are PRRs that upon recognition of
pathogen-associated molecular patterns (PAMPs) can
induce triggering of innate immune response [18].
When immature DCs (iDCs) are activated by TLR
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that express high levels of MHC class I andMHC class
II antigens as well as costimulatory molecules (CD80,
CD86), which are required for stimulation of na€ıve
T cells [19,20]. Because HCT setting is characterized
by an inflammatory environment with abundant
PAMPs derived from endogenous pathogens and
host tissue damaged by the high-dose chemotherapy
and radiation [21-23], we hypothesized that DCs
should augment NK cell function and thereby reduce
the risk of leukemia relapse after transplantation. To
test this hypothesis, we conducted laboratory and
clinical studies in parallel to examine the effects of
blood DC subsets on NK cells in HCT setting.MATERIALS AND METHODS
Antibodies, TLR Ligands, and Cell Lines
The following fluorochrome-labeled monoclonal
antibodies (mAbs) against humanantigenswereobtained
from BD Pharmigen (San Jose, CA): CD3-APC, CD8-
PECy7, CD11c-APC, CD14-APCCy7, CD19-
APCCy7, CD20-PE, CD45-FITC, CD69-FITC,
CD80-FITC, CD81-PE, CD83-PECy5, CD123-PE,
NKG2D-APC, IFN-g-FITC, IFN-g-PECy7, Lin
markers cocktail-FITC, Phospho-Zap70 (Y319)/
Syk (Y352)-PE, and Phospho-SLP-76 (pY128)-PE.
Fluorochrome-labeled mAbs CD25-PE, CD9-FITC,
and CD19-PE were obtained from DAKO (Carpinte-
ria, California). Fluorochrome-labeled mAbs CD3-
ECD, CD45-ECD, CD56-APC, CD86-PE, and
HLA DR-ECD were obtained from Beckman Coulter
(Fullerton, CA). Fluorochrome-labeled mAbs CD1c
(BDCA1)-PE and CD304 (BDCA4)-APC were ob-
tained from Miltenyi Biotec (Auburn, CA).
A-Class CpG ODN 2216 50-ggGGGAGCATGC
TGgggggG-30 as TLR9 ligand was provided by Hart-
well Center for Bioinformatics and Biotechnology at
St. Jude’s Children’s Research Hospital. Lipopolysac-
charide (LPS, Sigma 0127:B8) was used as a TLR4
ligand.
K562 leukemia cell lines were used as targets for
NK cell natural cytotoxicity assays. Luciferase trans-
duced neuroblastoma cell line (NB1691luc) was kindly
provided by Dr. A. Davidoff (St. Jude’s Children’s
Research Hospital) and was used as the target in
a quantitative in vivo mouse model.Isolation and Culture of NK Cells and DC
Subsets
NK cells were magnetically isolated from nonmo-
bilizied apheresis products of healthy donor using the
AutoMACS machine and NK cell isolation kit from
Miltenyi Biotec following the manufacturer’s specifi-
cations. From each 1-2  108 peripheral bloodmononuclear cell (PBMC) product, we typically
obtained between 5 to 15  106 cells with a purity of
always.95%CD561CD32 cells. Donor HLA typing
was not performed.
BDCA11 myeloid DCs and BDCA41 pDCs were
magnetically isolated using the AutoMACS machine
and Human CD1c (BDCA1) dendritic cell isolation
kit and CD304 (BDCA-4/Neuropilin-1) kits from
Miltenyi Biotec following themanufacturer’s specifica-
tions. Startingwith 2-8 109PBMCs, between 0.5-5
106 cells were typically obtained after the isolation
procedures ending with a purity always .95% for
BDCA41 cells and .90% for BDCA11 cells. High
levels of expression of TLR9 in purified BDCA41
cell products and TLR4 in purified BDCA11 products
were confirmed by RTPCR.
Freshly purified NK cells were cocultured with or
without DC subsets in a cell ratio of 2:1 overnight
with or without adding LPS 100 ng/mL or a-CpG
10 mg/mL. Cultures were performed in complete
culture medium (RPMI 1640 supplemented with
10% of heat-inactivated fetal bovine serum (FBS),
100 IU/mL penicillin, 100 ng/mL streptomycin, and
2 mM/L-glutamine) in a humidified atmosphere of
5% CO2 and 95% air, with no addition of exogenous
cytokines such as IL-2 or IL-15.DCmaturationwas as-
sessed usingCD80,CD83, andHLA-DRmAbs.CD69
andCD25were used to assessNKcell activation status.RT-PCR and Real-Time PCR for TLR
RNA was isolated with RNAeasy (Qiagen 2001,
Chatsworth, CA). DNA was removed by digestion
with 5Udeoxyribonuclease I (Boehringer, Indianapolis,
IN) for 30 minutes at 37C. Reverse transcription (RT)
was performedwith oligo-dT primer (Omniscript, Qia-
gen 2004). The PCR reaction volume was 50 mL, con-
taining 0.5 mM of each primer, 200 mM of each dNTP,
and 2.5unitsHotStarTaq (Qiagen2005).The following
sets of primers were used: TLR4 (F: 50-CTGCAAT
GGATCAAGGACCA-30, R: 50-TTATCTGAAGGT
GTTGCACATTCC-30) and TLR9 (F: 50-TGAAG
ACTTCAGGCCCAACTG-30, R: 50-TGCACGGTC
ACCAGGTTGT-30). A GeneAmp PCR System 9700
(Perkin-Elmer/Applied Biosystems, Bedford, MA) was
used with an initial denaturation step of 95C for 15
minutes, followed by 35 cycles of 94C for 30 seconds,
55C for 30 seconds (annealing temperature), 72C for
1minute (extension temperature), and a final elongation
step of 72C for 7 minutes.
Real-time quantitative PCR (RQ-PCR) was per-
formed by using the ABI Prism 7700 Sequence Detec-
tor Systems (Applied Biosystems) and the SYBRGreen
I Dye assay chemistry, as suggested by the manufac-
turer. Briefly, all reactions were performed with 2 mL
(80 ng) of cDNA, 12.5 mL of SYBR GREEN PCR
master mix (Applied Biosystems), and 0.5 mM forward
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A water control and melting curve analysis were always
performed to confirm the specificity of the PCR.
GAPDH was used as an internal control to normalize
the difference in the amount of cDNA contained in
each initial reaction. Reactions were incubated for 2
minutes at 50C, denatured for 10 minutes at 95C,
and subjected to 40 2-step amplification cycles with
annealing/extension at 60C for 1 minute followed
by denaturation at 95C for 15 seconds.
Phospho-protein Assay of NK Cells Stimulated
with TLR Ligands
NK cell signaling after direct TLR ligand stimula-
tion was determined by multiparameter intracellular
phospho-proteins assay using flow cytometry. In brief,
1  106 unstimulated NK cells or NK cells stimulated
with LPS or a-CpG were fixed after different time
points (0, 30, 60, 90, 120, 150, 180, 210, 240, 270,
300 seconds, 15, 30 minutes, and 8 hours) by adding
4% formaldehyde directly into the culture medium
to obtain a final concentration of 2% formaldehyde.
NK cells were incubated in fixative for 10 minutes at
ambient temperature and pelleted. They were then
permeabilized by resuspending with vigorous vortex-
ing in 500 mL of ice-coldMeOHper 106 and incubated
at 4C for 30 minutes. After that, cells were washed
twice in staining medium (PBS containing 1% BSA)
and then resuspended in staining medium at 0.5-1 
106 cells per 100 mL. Fluorophore-specific mAbs
were added and incubated for 15 to 30 minutes at am-
bient temperature. The cells were washed with 15 vol-
umes of staining medium and pelleted. Finally,
samples were resuspended in 100 mL of staining me-
dium and analyzed. At the same time points, intracel-
lular IFN-g staining was analyzed with mouse
antihuman-IFN-g clone 4S.B3.
Cytokine Array
Purified NK cells (2  105), with or without DC
subsets (1  105), were cultured in 48-well plates in
0.4 mL of complete culture medium and incubated
with or without 10 mg/mL CpG or 100 ng/mL LPS at
37C and 5% CO2. After 15 h of incubation, culture
supernatants were collected and analyzed for cytokine
production by ELISA using the Bioplex Protein Array
system(BioRad,Hercules,CA) according to the instruc-
tions of the manufacturer. Data analyses of all assays
were performed with the Bio-Plex Manager software.
Cytotoxicity Assays
Natural cytotoxicity of NK cells was assessed in
a conventional 2-hour europium-TDA release assay
(Perkin-Elmer Wallac, Turku, Finland) [24]. The fol-
lowing formulas were used to calculate spontaneous
and specific cytotoxicity:% Specific release
5ðExperimental release2spontaneous releaseÞ=
ðMaximum release2spontaneous releaseÞ
 100:
% Spontaneous release
5

Spontaneous release background

Maximum release background 100:
NK Cell Suppression by IL-6 and IL-10
Purified NK cells were incubated at 37C with var-
ious concentrations of recombinant human IL-6 or re-
combinant human IL-10 (R&D Systems, Minneapolis,
MN). Cytotoxic function of NK cells was determined
using a standard europium-release assay as described
above after 48 hours of incubation.Mouse Model of Metastatic Neuroblastoma
Six- to 8-week-old NOD-scid IL2Rgnull mice were
sublethally irradiated with 200 cGy and 24 hours later
they were injected intravenously with NB-1691luc 5
105 neuroblastoma cells. Intravenous NK cellular
therapy began 7 days after the injection of tumor cells
and was performed once a week for 3 weeks. In 3 inde-
pendent experiments (15 mice per group), we com-
pared untreated mice (control group) with mice
receiving 1  106 NK cells stimulated overnight with
10 mg/mL a-CpG (NK1CpG group), or mice receiv-
ing 1 106 NK cells and 5 105 BDCA4 in coculture
overnight with 10 mg/mL a-CpG (NK 1 CpG 1
BDCA4 group). Bioluminescence imaging was per-
formed after the initiation of NK cell therapy on
days 7, 14, and 21 after intraperitoneal (i.p.) injection
of 200 mL of luciferin dissolved in phosphate-
buffered saline (PBS) at a concentration of 15 mg/
mL. Between 7 and 10 minutes after administration
of substrate, animals were anesthetized using isofluor-
ane and transferred to the Xenogen IVIS-200 Imaging
system (Xenogen Corporation, Hopkinton, MA). Im-
ages were captured at varied exposures and analysis
performed using Xenogen Living Image Software
(version 2.50). For BLI plots, a rectangular region of
interest (ROI) encompassing the entire thorax and
abdomen was applied for each mouse and total flux
(photons/second [p/s]) calculated in ventral and prone
positions at different exposures (1, 10, 60, and 120
seconds). This value was scaled to a comparable back-
ground value (from a nontumor-bearing, luciferin-
injected control mouse). All experiments were con-
ducted following the guidelines of the Institutional
Animal Care and Use Committees according to crite-
ria outlined in the NIH Guide for Care and Use of
Laboratory Animals.
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Patients received either total-body irradiation
(TBI, 12Gy) with thiotepa (10 mg/kg) and cyclophos-
phamide (120 mg/kg), or a non-TBI regimen with flu-
darabine (150 mg/m2), thiotepa (10 mg/kg), and
melphalan (140 mg/m2). Post-HCT, patients required
only single agent GVHD prophylaxis with cyclospor-
ine or mycophenolate, because all the grafts were
depleted of CD31 cells by immunomagnetic method
using the CliniMACs system (Miltenyi). The number
of BDCA11 cells and BDCA41 cells in the parental
grafts after T cell depletion were measured by flow
cytometry analysis.Statistical Analyses
The risk of leukemia relapse and death after HCT
was estimated and compared by using the Kaplan-
Meier method and log-rank test among patients who
were categorized in tertiles based on the number of do-
nor BDCA11 cells (\0.5, 0.5-1.0, and .1.0  108) or
BDCA41 cells (\1.4, 1.5-2.5, and .2.5  108) in the
grafts. Other risk factor analyses included age, primary
diagnosis, degree of HLA match, conditioning,
GVHD prophylaxis, history of GVHD, and remission
status. The standard risk category consisted of patients
with acute myelegenous leukemia (AML), acute lym-
phobalstic leukemia (ALL), or non-Hodgkin leukemia
(NHL) in first or second complete remission. The
high-risk category included patients in third or subse-
quent remission, in relapse, or with myelodysplastic
syndrome (MDS).
The effects of blood DCs on the cytokine produc-
tion and cytotoxicity of NK cells in vitro were evalu-
ated by Wilcoxon rank sum tests. The dose-response
suppressive effects of IL-6 and IL-10 on NK cell cyto-
toxicity were analyzed by trend test. The difference in
total flux in bioluminescence was compared using
repeated-measures analysis of variance (ANOVA).Figure 1. TLR signaling in purified NK cells. Phosphorylation of (A)
ZAP70/SYK and (B) SLP76 in purified NK cells after incubation with
10 mg/mL of a-CpG (blue) or 100 ng/mL of LPS (pink), with resultant in-
crease in (C) IFN-g production. Data are expressed as means6 SEM of
3 different experiments.RESULTS
Phenotypic Changes in Coculture of NK Cells
and Blood DC Subsets
Highly purified CD56132 NK cells were colocal-
ized in our in vitro culture systemwith either BDCA11
myeloid DCs or BDCA41 pDCs for 24 hours in cell
ratio of 2:1.We observed an increase in surface expres-
sion in both DC subsets of costimulatory molecules
(CD80), maturation markers (CD83), andMHCClass
II (HLA-DR); all of these changes suggested the blood
DCs were undergoing maturation in the in vitro sys-
tem. In turn, both DC subsets were able to activate
NK cells phenotypically, as indicated by the induction
of CD69 and CD25 expression on NK cells.Suppression of TLR-Ligand Effect on NK Cell by
Blood DC
On the basis of the phenotypic changes described
above, we hypothesized that human blood DCs should
augment the function of NK cells in the presence of
TLR ligands in the HCT setting. To test this hypoth-
esis, we examined the direct effect of TLR ligands on
NK cells and the secondary effects through DCs. We
found that both TLR4 and TLR9 were expressed on
highly purifiedNK cells as determined byRT-PCR as-
say, but the level of mRNA did not change with ligand
exposure as demonstrated by RQ-PCR analysis (mean
delta, cycle threshold (CT) 7.9 6 1.4 versus 7.7 6 1.1
for TLR4, and 5.86 1.7 versus 5.46 1.4, respectively,
all P. .48). Importantly, the TLRs were functional as
demonstrated by positive ZAP70/SYK and SLP76 sig-
naling and a rise in production of IFN-g (Figure 1).
Furthermore, TLR ligands increased the secretion of
IFN-g byNK cells (Figure 2A) and enhanced the cyto-
toxicity against K562 cells (Figure 2B). Surprisingly,
both BDCA11 myeloid DC and BDCA41 pDC
Figure 2. Effects of TLR ligands and blood DC subsets on IFN-g secre-
tion and natural cytotoxicity of NK cells. (A) IFN-g secretion by unsti-
mulated NK cells (NK), NK cells stimulated overnight with 100 ng/mL of
LPS (NK1 LPS) or 10 mg/mL of a-CpG (NK1CpG), and NK cells stim-
ulated overnight with 1 of these two TLR ligands in the presence of
BDCA11 myeloid DCs (NK 1 LPS 1 BDCA1) or BDCA41 pDCs
(NK 1 CpG 1 BDCA4) in a starting 2:1 cell ratio (no change in cell
number or ratio thereafter was observed overnight). Results are
expressed as means 6 SEM from 3 independent experiments. (B)
Cytotoxicity against K562 cells (NK:K562 cell ratio were always 8:1)
by unstimulated NK cells (NK), NK cells stimulated overnight with
100 ng/mL of LPS (NK 1 LPS) or 10 mg/mL of a-CpG (NK 1 CpG),
and NK cells stimulated overnight with 1 of these two TLR ligands in
the presence of BDCA11 myeloid DCs (NK 1 LPS 1 BDCA1) or
BDCA41 pDCs (NK 1 CpG 1 BDCA4) in a NK:DC cell ratio of
2:1. After cocultured, NK cells were not further purified. Results are ex-
pressed as means 6 SEM from 3 independent experiments. *P\.05.
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induced by TLR ligands (Figure 2A). In addition,
BDCA41 pDC were able to reduce the stimulation ef-
fect of a-CpG on NK cytotoxicity against K562 cells,
whereas BDCA11myeloidDCcould completely offset
the effect of LPS (Figure 2B).
We then extended our investigation to an in vivo
model to examine whether the modest suppressive ef-
fect of BDCA41 pDC on TLR ligand stimulated NK
cells in vitro might be clinically meaningful.We found
that BDCA41 pDC were indeed able to suppress theantitumor effect of CpG-activated NK cells (P\ .05)
(Figure 3).
Higher Risk of Relapse and Poorer Survival in
Patients with Childhood Leukemia after
Receiving Higher Dose of Blood DCs
To examine the effects of DC subsets on patient
outcomes, we studied 47 patients with AML (n 5 17),
ALL (n 5 25), or NHL (n 5 5) who received an
HCT from a HLA-haploidentical parental donor.
We measured the number of DC in the patient’s graft
prospectively and categorized them into tertiles based
on the DC content. We found that those patients
who had in their graft a higher number of BDCA11
myeloid DC (upper tertile) or BDCA41 pDC (upper
2 tertiles) had poorer survival because of increased inci-
dence in leukemia relapse (Figure 4). No other factors
were found to be statistically significant, including age,
primary diagnosis, risk group, degree of HLA match-
ing, conditioning, GVHD prophylaxis, or history of
GVHD (all P . .16). The number of BDCA11 or
BDCA41 DCs in the graft has no effect on
transplant-related mortality (P. .36).
Inhibition of NK Cells by DCs Through
IL-6 and IL-10
To investigate the mechanisms of the suppressive
effects of blood DCs on NK cells activated by TLR li-
gands, we examined the cytokine profile of the in vitro
cocultures. We found that in the presence of BDC11
myeloid DC or BDC41 pDC, there was a large
amount of IL-10 (mean 600 pg/mL) or IL-6 (mean
2000 pg/mL), respectively (Figure 5A). Incubation of
NK cells with recombinant IL-6 or IL-10 at these
cytokine concentrations confirmed a dose-dependent
suppressive effects on the cytotoxic function of NK
cells (Figure 5B).DISCUSSION
In this study, we sought to prove that blood DCs
augmented NK cell function and thus favored the clini-
cal activity of NK cells against AML [5] and ALL [7].
Our hypothesis was based on the large body of litera-
tures supporting a critical role ofDC andNKcell cross-
talk in the control of infection [18,25-27]. Surprisingly,
we found that although, phenotypically, NK cells could
induce DC maturation and DCs could in turn increase
the expression of activating markers in NK cells as
described by other investigators, paradoxically, both
blood BDCA11 myeloid DC and BDCA41 pDC
suppressed the function of NK cells in both in vitro
assays and in vivo mouse models when TLR ligands
were used to mimic the microbe-associated inflamma-
tory environment in allogeneic HCT [28]. The clinical
relevance of these finding is underscored by our
Figure 3. Suppressive effect of BDCA41 cells on the antitumor response of NK cells. Quantitative ventral photon counting analysis on days 7, 14, and
21 after the initiation of NK cell therapy in a metastatic neuroblastoma mouse model. Animals either received no treatment (Untreated), or received
treatment with NK cells stimulated overnight with 10 mg/mL of a-CpG (NK1 CpG), or NK cells stimulated with a-CpG in the presence of BDCA41
pDCs (NK1CpG1 BDCA4) in a 2:1 cell ratio. Results are representative of and summarized from 3 independent experiments (means6 SD) at various
time points after receiving NK cellular therapy.
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haploidentical graft containing large number of
BDCA11 myeloid DC and BDCA41 pDC had a high
risk of leukemia relapse. Detailed biologic studies reveal
thatDCwereapotent inhibitorofbothNKcell cytotox-
icity and cytokine production and were mechanistically
mediated in part through IL-10 or IL-6. These findings
have significant implications for future HCT strategies.
NK cell function is tightly regulated by a balance of
signals from inhibitory and activating receptors. The
‘‘missing-self’’ hypothesis suggests that NK cell speci-
ficity is determined by the interaction between NK
cell inhibitory receptors and target cell MHC class I ex-
pression [29]. Even in the absence of a target cell major
histocompability complex (MHC), however, most acti-
vating receptor-ligand interactions are insufficient to
induce cytotoxicity by resting peripheral-blood NK
cells [30]. Except for CD16, preactivation of NK cells
is required to generate sufficient signal for cytolytic
granule polarization and degranulation [31,32]. NK
cell may be preactivated by many non-antibody-
directed cell-mediated cytotoxicity (ADCC) factors
such as cytokines or pathogen-derived substances [30].
TLR ligands are pathogen-derived substances that can
activate NK cell indirectly through accessory cells
[33,34] or directly through TLR expressed on NK
cells [35-37]. It remains controversial on the level ofexpression of each of the 10 TLR family members on
human NK cells, and their ability to directly activate
NK cells. For example, some studies failed to show
the expression of TLR9 on human NK cells and
direct activation by its ligands [33,34], whereas others
demonstrated its expression and function [36,38].
TLR3 was found to be expressed at a higher level
than TLR1 in some studies [35], but a reverse order
was observed by others [33]. Furthermore, some found
significant TLR4 expression on humanNK cells and its
ability to directly trigger cytokine production and cyto-
toxicity [35,37]; however, others did not observe any
significant TLR4 expression or direct function
[33,34]. Differences in NK cell gating or purification
strategy, culture condition, induction status, and the
amount or type of ligand used may explain the
differences between previous reports [34,38,39]. In
our study, we found that human NK cells expressed
TLR9 in addition to TLR4, as evidenced by the
presence of mRNA in highly purified NK cells. More
importantly, we showed that they were functionally
responsive directly to TLR ligands in the absence of
DCs, and both TLR-ligands were capable of stimulat-
ing NK cells with resultant signaling through ZAP70/
Syk and SLP 76 phosphorylation. The end results
were activation of NK cells to produce IFN-g and in-
creased killing of target cells both in vitro and in vivo.
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Figure 4. Cumulative risk of leukemia relapse after HCT. The risk of leukemia relapse after transplant was evaluated based on the graft’s DC content in
tertiles: (A) BDCA11 cells (0.5, 0.5-1.0,.1.0 108) or (B) BDCA41 cells (\1.4, 1.5-2.5, and.2.5 108). Those patients who had received a hema-
topoietic graft containing (C) the upper tertile of BDCA11 myeloid DCs or (D) the upper two tertiles of BDCA41 pDCs (high number) had a higher
risk of relapse when compared with those who received fewer DCs (low number), P\.05.
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activated NK cells in cancer immunotherapy. Clinical
scale isolation ofNK is now feasible with no contamina-
tion of DCs [40,41]; thus, NK cells stimulated ex vivo
by the TLR ligand may be used for cancer treatment.Figure 5. Role of IL-6 and IL-10. (A) IL-10 and IL-6 levels in the supernatant o
overnight with 100 ng/mL of LPS (NK1 LPS) or 10 mg/mL of a-CpG (NK1CpG
BDCA11 myeloid DCs (NK1 LPS1 BDCA1) or BDCA41 pDCs (NK1 Cp
from 3 independent experiments. *P\.05 (B) Suppressive effect of IL-6 and IL-1
soluble IL-10 or IL-6 (with no DCs or TLR ligands) for 48 hours resulted in r
dependent manner (P\.05 for the two highest concentrations of IL-6 and IL-1
by Wilcoxon rank sum test and trend test).In this regard, recent studies suggested that TLR
ligands may improve the efficacy of immunotherapy
for chronic lymphocytic leukemia and NHL by
enhancing NK cells and T cells and by altering the
tumor microenvironment in angiogenesis [42,43].f cell cultures including unstimulated NK cells (NK), NK cells stimulated
), and NK cells stimulated with these two TLR ligands in the presence of
G1 BDCA4) in a 2:1 cell ratio. Results are expressed as means6 SEM
0 on natural cytotoxicity of NK cells. Incubation of purifiedNK cells with
eduction of natural cytotoxicity against K562 cells (E:T; 2:1) in a dose-
0 when compared with no cytokines, and for dose-response as analyzed
Figure 6. Two-signal model in HCT for leukemia. In the presence of
leukemia cells and TLR ligands (first signal), various immune cells may
provide NK cells a different second signal (A) toward ‘‘effector’’ and
‘‘helper’’ phenotype, or (B) toward ‘‘indolent’’ and ‘‘tolerant’’ phenotype.
The NK cell effects on leukemia may be direct (solid arrows), especially
in T cell–depleted HCT setting as described herein, or mediated
through T cell priming (dotted arrows).
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sue require both the engagement of activating recep-
tors and the presence of activating cytokines released
by DCs [44]. Colocalization of NK cells with both
monocyte-derived DCs and pDCs in inflamed tissue
is in part mediated by chemerin [45]. In a ‘‘2-signal’’
model [44,46], functionally and phenotypically
divergent types of NK cells may be generated after
receiving a first signal from tumor cells or via TLRs,
and then a second signal delivered through various
cytokines released by different immune cells
(Figure 6). In the classical model of viral infection,
IL-12 produced by peripheral tissue-resident DCs
favors the development of CD251CD691 ‘‘effector’’
NK cells, which in turn promote optimal maturation
of DCs characterized by up-regulation of MHC,
CCR7, CD80, and CD86 [47]. The mature DCs
then migrate to the secondary lymphoid tissues to pro-
mote Th1 polarization. Those inappropriately primed
DC in the inflamed tissue will be killed by the effector
NK cells (termed NK-mediated editing). Alterna-
tively, under the influence of IL-18, NK cells mayacquire a ‘‘helper’’ phenotype with de novo expression
of CCR7, thus enabling them to be responsive to
CCL19/21. These helper NK cells may then migrate
to the secondary lymphoid tissues themselves, and
work together with DCs to release large amount of
IFN-g for T cell priming [48,49].
Recent studies, however, have demonstrated that
not all interactions among NK cells and other innate
immune cells may result in induction of NK cell prim-
ing and Th1 polarization. For example, exposure of
NK cells to IL-4 released by mastocytes and eosino-
phils may lead NK cells toward an ‘‘indolent’’ NK
phenotype and impair NK-mediated DC editing
(Figure 6) [50]. In this study, we extend the 2-signal
model further by demonstrating for the first time
that circulating myeloid DCs and pDCs, unlike pe-
ripheral tissue–resident DCs, may favor an IL6-or
IL10-rich milieu, respectively, to tolerize NK cells
and promote tumor cell growth. Although the source
of these 2 cytokines has not been established, the pres-
ence of either BDCA11 or BDCA41 DCs clearly
resulted in a significant decrease in TLR ligand–
induced production of IFN-g and a reduction in
killing of target cells by NK cells in vitro and in vivo.
Both IL-6 and IL-10 are a pleiotropic cytokine with
dual immunosuppressive and immunostimulatory
properties as well as tumor-promoting and tumor-
inhibitory effects [51,52]. For instance, IL-6 is
considered an activator of acute phase response and
a lymphocyte stimulatory factor [53], but it can also
block neutrophil accumulation, DC development,
NF-kB binding activity, CCR7 expression, and mixed
lymphocyte reaction [54-56]. On the other hand, IL-
10 was originally termed cytokine synthesis inhibitory
factor and suppresses NF-kB through STAT3 in DCs
and CD41 T cells, but paradoxically, it can also acti-
vate NF-kB and AP-1 in CD81 T cells to increase its
cytotoxicity [51,57]. Because the effects of blood
DCs on NK cells is suppressive as demonstrated
herein and are mechanistically mediated through IL-
6 and IL-10, our findings should encourage further
study of novel medical therapy to block the secretion
of these 2 cytokines or to neutralize their activity to
improve NK therapeutic potential. Clinical grade
antibodies are now available for both IL-6 and IL-10
[51,58].
Our finding that patients who received an HLA-
haploidentical graft containing larger numbers of
BDCA11 DC and BDCA41 DC had a higher risk of
leukemia relapse and poorer survival rate should have
immediate implications in clinical HCTs. First, it pro-
vides a novel prognostic factor in the management of
haploidentical HCT patients. Second, the data suggest
that DC depletion from the donor graft should be con-
sidered in haploidentical HCT for leukemia, as blood
DCs may not only inhibit NK cells, but also contain
some circulating tolerogenic DC subsets [59,60]. DC
606 Biol Blood Marrow Transplant 17:598-607, 2011A. Perez-Martinez et al.depletion can be accomplished by directly removing
DCs from the hematopoietic graft, or indirectly
through positive selection of stem cells using markers
such as CD133 or CD34, which are commonly used
in the clinic [61].
In summary, our study provides fundamental in-
sights into the biology of blood DC subsets and NK
cells in the presence of TLR ligands as in the setting
of HCTs. Laboratory and clinical data provide strong
evidence for a dominant suppressive effect of BDCA11
myeloid DCs and BCDCA41 pDCs. These results
should have significant implications for future medical
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